Inhibition of p38/Mk2 signaling pathway improves the anti-inflammatory effect of WIN55 on mouse experimental colitis

Laboratory Investigation

Volumn 93, Issue 3, 2013, Pages 322-333

  Li, Yu Y ^a   Yuece, Birol ^b   Cao, Hua M ^a   Lin, Hong X ^a   Lv, Shuai ^a   Chen, Jie C ^a   Ochs, Stephanie ^b   Sibaev, Andrej ^b   Deindl, Elisabeth ^b   Schaefer, Claus ^b   Storr, Martin ^b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

cannabinoids; inflammation; Mk2; mouse DDS colitis; p38 MAP kinases

Indexed keywords

CANNABINOID RECEPTOR AGONIST; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT 1; DEXTRAN SULFATE; ENDOCANNABINOID; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; COLITIS; CONTROLLED STUDY; FEMALE; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RECTUM HEMORRHAGE; WEIGHT REDUCTION; WILD TYPE;

EID: 84874588354     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2012.177     Document Type: Article

References (51)

1. Baumgart DC, Carding SR. Inflammatory bowel disease: Cause and immunobiology. Lancet 2007;369:1627-1640
2. Rijnierse A, Nijkamp FP, Kraneveld AD. Mast cells and nerves tickle in the tummy: Implications for inflammatory bowel disease and irritable bowel syndrome. Pharmacol Ther 2007;116:207-235
3. Choi SY, Hur SJ, An CS, et al. Anti-inflammatory effects of Inonotus obliquus in colitis induced by dextran sodium sulfate. J Biomed Biotechnol 2010;2010:943516
4. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001;410:37-40
5. Hollenbach E, Vieth M, Roessner A, et al. Inhibition of RICK/nuclear factor-kappaB and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease. J Biol Chem 2005;280:14981-14988
6. Hommes D, van den Blink B, Plasse T, et al. Inhibition of stressactivated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002;122:7-14
7. Scaldaferri F, Correale C, Gasbarrini A, et al. Molecular signaling blockade as a new approach to inhibit leukocyte-endothelial interactions for inflammatory bowel disease treatment. Cell Adhes Migr 2009;3:296-299
8. Fiocchi C. Intestinal inflammation: A complex interplay of immune and nonimmune cell interactions. Am J Physiol 1997;273:G769-G775
9. Danese S, Semeraro S, Marini M, et al. Adhesion molecules in inflammatory bowel disease: Therapeutic implications for gut inflammation. Dig Liver Dis 2005;37:811-818
10. Hollenbach E, Neumann M, Vieth M, et al. Inhibition of p38 MAP kinase-and RICK/NF-kappaB-signaling suppresses inflammatory bowel disease. FASEB J 2004;18:1550-1552
11. Kotlyarov A, Neininger A, Schubert C, et al. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol 1999;1:94-97
12. Ronkina N, Kotlyarov A, Dittrich-Breiholz O, et al. The mitogenactivated protein kinase (MAPK)-activated protein kinases MK2 and MK3 cooperate in stimulation of tumor necrosis factor biosynthesis and stabilization of p38 MAPK. Mol Cell Biol 2007;27:170-181
13. Kotlyarov A, Yannoni Y, Fritz S, et al. Distinct cellular functions of MK2. Mol Cell Biol 2002;22:4827-4835
14. Li YY, Ochs S, Gao ZR, et al. Regulation of HSP60 and the role of MK2 in a new model of severe experimental pancreatitis. Am J Physiol Gastrointest Liver Physiol 2009;297:G981-G989
15. Tietz AB, Malo A, Diebold J, et al. Gene deletion of MK2 inhibits TNFalpha and IL-6 and protects against cerulein-induced pancreatitis. Am J Physiol Gastrointest Liver Physiol 2006;290:G1298-G1306
16. Thomas T, Timmer M, Cesnulevicius K, et al. MAPKAP kinase 2-deficiency prevents neurons from cell death by reducing neuroinflammation -relevance in a mouse model of Parkinson's disease. J Neurochem 2008;105:2039-2052
17. Martin F, Matthias P. Factors associated with the subject's ability to quantify their lumbar flexion demands at work. Int J Environ Health Res 2006;16:69-79
18. Di Marzo V. Targeting the endocannabinoid system: To enhance or reduce? Nat Rev Drug Discov 2008;7:438-455
19. Li YY, Li YN, Ni JB, et al. Involvement of cannabinoid-1 and cannabinoid-2 receptors in septic ileus. Neurogastroenterol Motil 2010;22:350-e388
20. Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-564
21. Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut 2001;48:859-867
22. Massa F, Marsicano G, Hermann H, et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 2004;113:1202-1209
23. Buckley NE. The peripheral cannabinoid receptor knockout mice: An update. Br J Pharmacol 2008;153:309-318
24. Wright KL, Duncan M, Sharkey KA. Cannabinoid CB2 receptors in the gastrointestinal tract: A regulatory system in states of inflammation. Br J Pharmacol 2008;153:263-270
25. Izzo AA, Mascolo N, Capasso F. The gastrointestinal pharmacology of cannabinoids. Curr Opin Pharmacol 2001;1:597-603
26. Storr MA, Yüce B, Andrews CN, et al. The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome. Neurogastroenterol Motil 2008;20:857-868
27. Fitzpatrick LR, Deml L, Hofmann C, et al. 4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease. Inflamm Bowel Dis 2010;16:1763-1777
28. Cooper HS, Murthy SN, Shah RS, et al. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993;69:238-249
29. Hartmann G, Bidlingmaier C, Siegmund B, et al. Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. J Pharmacol Exp Ther 2000;292:22-30
30. Siegmund B, Rieder F, Albrich S, et al. Adenosine kinase inhibitor GP515 improves experimental colitis in mice. J Pharmacol Exp Ther 2001;296:99-105
31. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159
32. Tolstanova G, Deng XM, French SW, et al. Early endothelial damage and increased colonic vascular permeability in the development of experimental ulcerative colitis in rats and mice. Lab Invest 2012;92:9-21
33. Whittem CG, Williams AD, Williams CS. Murine colitis modeling using dextran sulfate sodium (DSS). J Vis Exp 2010;35:1652
34. Diaz-Granados N, Howe K, Lu J, et al. Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity. Am J Pathol 2000;156:2169-2177
35. Hanauer SB. Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006;12(Suppl 1):S3-S9
36. Van Assche G, Vermeire S, Rutgeerts P. Focus on mechanisms of inflammation in inflammatory bowel disease sites of inhibition: Current and future therapies. Gastroenterol Clin N Am 2006;35:743-756
37. Broom OJ, Widjaya B, Troelsen J, et al. Mitogen activated protein kinases: A role in inflammatory bowel disease? Clin Exp Immunol 2009;158:272-280
38. Scaldaferri F, Sans M, Vetrano S, et al. The role of MAPK in governing lymphocyte adhesion to and migration across the microvasculature in inflammatory bowel disease. Eur J Immunol 2009;39:290-300
39. Saklatvala J, Dean J, Clark A. Control of the expression of inflammatory response genes. Biochem Soc Symp 2003;70:95-106
40. Watanabe T, Higuchi K, Hamaguchi M, et al. Monocyte chemotactic protein-1 regulates leukocyte recruitment during gastric ulcer recurrence induced by tumor necrosis factor-alpha. Am J Physiol Gastrointest Liver Physiol 2004;287:G919-G928
41. Rosenthal LA, Amineva SP, Szakaly RJ, et al. A rat model of picornavirus-induced airway infection and inflammation. Virol J 2009;6:122
42. Kinoshita K, Horiguchi K, Fujisawa M, et al. Possible involvement of muscularis resident macrophages in impairment of interstitial cells of Cajal and myenteric nerve systems in rat models of TNBS-induced colitis. Histochem Cell Biol 2007;127:41-53
43. Long JZ, Li W, Booker L, et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 2009;5:37-44
44. Wit RD, Boonstra J, Verkleij AJ, et al. Large scale screening assay for the phosphorylation of mitogen-activated protein kinase in cells. J Biomol Screen 1998;3:277-278
45. Feng YJ, Li YY. The role of p38MAPK in the pathogenesis of inflammatory bowel disease. J Dig Dis 2011;12:327-332
46. Croci T, Landi M, Galzin AM, et al. Role of cannabinoid CB1 receptors and tumor necrosis factor-a in the gut and systemic anti-inflammatory activity of SR 141716 (Rimonabant) in rodents. Br J Pharmacol 2003;145:115-122
47. Kimball ES, Schneider CR, Wallace NH, et al. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol 2006;291:G364-G371
48. Hanson M, Bueno L, Fioramonti J. Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterol Motil 2006;18:949-956
49. Sheng WS, Hu S, Min X, et al. Synthetic cannabinoid WIN55, 212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 2005;49:211-219
50. Izzo AA, Camilleri M. Emerging role of cannabinoids in gastrointestinal and liver diseases: Basic and clinical aspects. Gut 2008;57:1140-1155
51. Kontoyiannis D, Boulougouris G, Manoloukos M, et al. Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's-like inflammatory bowel disease. J Exp Med 2002;196:1563-1574